Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Operating Activities:
Net loss	$ (13,172)	$ (17,340)	$ (13,840)	$ (16,598)	$ (30,512)	$ (30,438)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Depreciation					1,585	1,162
Amortization of intangible assets	2,862		2,619		5,729	5,183
Stock-based compensation					3,628	3,856
Gain on extinguishment of debt	(2,847)		0		(2,847)	0
Deferred tax benefit					(36)	(1,388)
Write down of inventory	200		0		288	0
Change in fair value of warrant liabilities	(0)		114		1,981	269
Change in fair value of contingent consideration	478		212		735	1,268
Changes in operating assets and liabilities:
Accounts receivable					127	(350)
Inventories					(1,687)	(2,332)
Operating lease right-of-use assets					(2,970)	546
Other current and long term assets					3,177	281
Accounts payable					679	(1,221)
Accrued expenses					(1,428)	(1,451)
Deferred revenue					14	22
Operating lease liabilities					3,052	(608)
Other long term liabilities					0	65
Net cash and cash equivalents used in operating activities					(18,485)	(25,136)
Investing Activities:
Purchase of property and equipment					(700)	(3)
Net cash and cash equivalents used in investing activities					(700)	(3)
Financing Activities:
Proceeds from issuance of common stock, preferred stock and warrants under 2020 financing, net of issuance costs					0	13,525
Proceeds from issuance of common stock, net of issuance costs					130,314	11,212
Proceeds from notes payable, net of issuance costs					0	2,815
Taxes paid related to net share settlement of vesting of restricted stock units					(1,041)	(33)
Payment of contingent consideration					0	(74)
Proceeds from exercise of stock options and warrants					30,835	3,340
Net cash and cash equivalents provided by financing activities					160,108	30,785
Effect of exchange rate changes on cash and cash equivalents					(329)	17
Net increase in cash, cash equivalents and restricted cash					140,594	5,663
Cash, cash equivalents and restricted cash, beginning of period		$ 17,529		$ 10,567	17,529	10,567	$ 10,567
Cash, cash equivalents and restricted cash, end of period	$ 158,123		$ 16,230		158,123	16,230	$ 17,529
Supplemental Schedule of Non-cash Investing and Financing Activities:
Transfer of inventories to property and equipment					1,243	3,403
Acquisition of property and equipment in accounts payable					67	0
Reclass of warrant liability to common stock and additional paid-in-capital					2,236	0
Lease liabilities arising from obtaining right-of-use assets					3,461	0
Exchange of common stock for Series B Warrants					0	2,470
Transfer of in-process research and development to intellectual property					0	2,425
Conversion of preferred stock to common stock					$ 0	$ 79